Previous close | 330.70 |
Open | 332.95 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's range | 329.37 - 342.33 |
52-week range | 231.87 - 384.44 |
Volume | |
Avg. volume | 2,930,562 |
Market cap | 322.186B |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 50.99 |
EPS (TTM) | 6.65 |
Earnings date | 27 Apr 2023 |
Forward dividend & yield | 4.52 (1.32%) |
Ex-dividend date | 14 Feb 2023 |
1y target est | 389.60 |
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.